Scholarlink

Abstract <p>The study aims to investigate methods for sensitizing malignant tumors to radiation therapy using [<sup>131</sup>I]I-labeled methylene blue in combination with DNA damage repair inhibitors. Studies showed that [<sup>131</sup>I]I-labeled methylene blue (with/without AraC) rapidly entered cells, with ~70% internalized within 3 h. Uptake decreased with a half-life of 3.5 days. Geant4 simulations calculated absorbed doses, revealing that the [<sup>131</sup>I]I-labeled methylene blue + AraC pair had an RBE of 5.13. Our findings indicate that in the presence of 1-β-D-arabinofuranosylcytosine (AraC), the survival fraction of irradiated B16F10 melanoma cells treated with iodine-131 is significantly reduced. This effect can be attributed to a decrease in cell proliferation in the overall population, as well as a reduction in the number of cancer stem cells specifically in the “AraC + I-131” group. These results hold promise for enhancing the efficacy of radionuclide therapy in the future.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Studying of Synergic Action of 1-β-D-Arabinofuranosylcytosine and Radionuclide Therapy with [131I]I-Labeled Methylene Blue on Surviving of B16F10 Melanoma Cells

  • 期刊论文

  • 发表日期：

    2026年2月8日

查看全文
  • A. S. Lunev,
  • K. A. Petrosova,
  • E. A. Krasavin,
  • A. B. Bruskin,
  • A. E. Zakharkina,
  • A. V. Boreyko,
  • A. N. Bugay

摘要

Abstract

The study aims to investigate methods for sensitizing malignant tumors to radiation therapy using [131I]I-labeled methylene blue in combination with DNA damage repair inhibitors. Studies showed that [131I]I-labeled methylene blue (with/without AraC) rapidly entered cells, with ~70% internalized within 3 h. Uptake decreased with a half-life of 3.5 days. Geant4 simulations calculated absorbed doses, revealing that the [131I]I-labeled methylene blue + AraC pair had an RBE of 5.13. Our findings indicate that in the presence of 1-β-D-arabinofuranosylcytosine (AraC), the survival fraction of irradiated B16F10 melanoma cells treated with iodine-131 is significantly reduced. This effect can be attributed to a decrease in cell proliferation in the overall population, as well as a reduction in the number of cancer stem cells specifically in the “AraC + I-131” group. These results hold promise for enhancing the efficacy of radionuclide therapy in the future.